Bayer and Atara Biotherapeutics (ATRA) Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. DPZ
6. NVDA
7. PRIM
8. META
9. SPY
10. SPCX

Go back to Bayer and Atara Biotherapeutics (ATRA) Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

December 6, 2020 11:00 PM EST

Agreement is fundamental element of Bayers new Cell & Gene Therapy strategy Bayer to enter CAR T-cell therapy space and expand oncology development pipeline with groundbreaking technology Recognizes the leading position of Ataras technology platform in allogeneic cell therapy Collaboration will focus on off-the-shelf T-cell immunotherapy ATA3271 for high mesothelin-expressing tumors Atara to receive upfront payment of USD 60 million, and up to a total of USD 610 million for development, regulatory and commercialization milestones, plus tiered royalties up to low double-digit percentage of net sales Atara to Host Conference... More